Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | CCR1 | P32246 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648009 | 0.83 | OPRM1 (0.68) | OPRM1DRD2DRD4DRD3CCR1 | |
| SCHEMBL1284714 | 0.83 | OPRM1 (0.71) | OPRM1KMT2A | |
| SCHEMBL4657165 | 0.83 | OPRM1 (0.71) | OPRM1KMT2A | |
| SCHEMBL3157118 | 0.83 | OPRM1 (0.97) | OPRM1KMT2A | |
| SCHEMBL1284273 | 0.83 | OPRM1 (0.71) | OPRM1KMT2A | |
| SCHEMBL504355 | 0.82 | OPRM1 (0.70) | OPRM1KMT2A | |
| SCHEMBL4656597 | 0.82 | OPRM1 (0.97) | OPRM1KMT2A | |
| SCHEMBL5758344 | 0.81 | KMT2A (0.66) | OPRM1KMT2A | |
| Hydrochloric Acid SCHEMBL3595890 | 0.81 | OPRM1 (0.73) | OPRM1KMT2A | |
| SCHEMBL1285120 | 0.81 | OPRM1 (0.68) | OPRM1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200054630-A1 | BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION | MINDIMMUNE THERAPEUTICS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-10238654-B2 | Benzamides-containing compounds and their use in the treatment of epilepsy | MINDIMMUNE THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-2906546-B1 | BENZAMIDES | H LUNDBECK AS (DK) | 2018-01-10 | — | — | EP | disclosed |
| US-20170202836-A1 | Benzamides-Containing Compounds and Their Use in the Treatment of Epilepsy | H. LUNDBECK A/S (DK) | 2017-07-20 | — | — | US | disclosed |
| US-9649308-B2 | Benzamide-containing compounds and their use in the treatment of pain | H. LUNDBECK A/S (DK) | 2017-05-16 | — | — | US | disclosed |
| US-20150283134-A1 | Benzamides | MINDIMMUNE THERAPEUTICS, INC. | 2015-10-08 | — | — | US | disclosed |
| CN-104884445-A | Benzamides | LUNDBECK & CO AS H | 2015-09-02 | — | — | CN | disclosed |
| EP-2906546-A1 | BENZAMIDES | H. Lundbeck A/S (DK) | 2015-08-19 | — | — | EP | disclosed |
| US-9102591-B2 | Benzamides | H. LUNDBECK A/S (DK) | 2015-08-11 | — | — | US | disclosed |
| US-9006430-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein | ASTEX THERAPEUTICS LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| US-20100022564-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (UK) | 2009-10-01 | — | — | US | disclosed |
| US-7462631-B2 | Thiophene-2-carboxamide derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2008-12-09 | — | — | US | disclosed |
| US-7462631-B2 | Thiophene-2-carboxamide derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2008-12-09 | — | — | US | disclosed |
| US-7345059-B2 | Diphenylpyridine derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2008-03-18 | — | — | US | disclosed |
| US-7345059-B2 | Diphenylpyridine derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2008-03-18 | — | — | US | disclosed |
| EP-1581495-B1 | 4-aryl-4-(naphth-1-ylmethylamino)methyl-piperidine compounds and their use | ASTRAZENECA AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| US-20060058352-A1 | Piperidine amine compounds and their use | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1581495-A1 | PIPERIDINE AMINE COMPOUNDS AND THEIR USE | AstraZeneca AB (SE) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004056771-A1 | PIPERIDINE AMINE COMPOUNDS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054630-A1 | BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION | P2RX5, P2RX7, P2RX2 | OPRM1 513/4885KMT2A 1410/4885DRD2 329/4885 |
| US-20060058352-A1 | Piperidine amine compounds and their use | HRH3, H1-5, H1-0 | OPRM1 161/4885KMT2A 245/4885DRD2 44/4885 |
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | CDK2, CDK1, OXSR1 | OPRM1 666/4885KMT2A 1446/4885DRD2 1476/4885 |
| US-10238654-B2 | Benzamides-containing compounds and their use in the treatment of epilepsy | P2RX5, P2RX7, P2RX6 | OPRM1 1643/4885KMT2A 854/4885DRD2 1448/4885 |
| US-20170202836-A1 | Benzamides-Containing Compounds and Their Use in the Treatment of Epilepsy | P2RX5, P2RX7, P2RX6 | OPRM1 1643/4885KMT2A 854/4885DRD2 1448/4885 |
| US-20150283134-A1 | Benzamides | P2RX7, TRPV1, P2RX5 | OPRM1 363/4885KMT2A 2723/4885DRD2 1575/4885 |
| US-20100022564-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | TPMT, CNKSR1, PRKD3 | OPRM1 345/4885KMT2A 2482/4885DRD2 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.